Bristol-Myers Squibb Benzodiazepinone Patent EP3793563A1 Published April 15

EPO published patent application EP3793563A1, an A1 publication (indicating both a search report and application as filed), on behalf of Bristol-Myers Squibb Company and Ayala Pharmaceuticals Inc. The application covers compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and associated therapeutic methods of use. The compound falls under IPC classification A61K 31/5513, with therapeutic applications including A61P 35/00 (antineoplastic) and A61K 45/06 (pharmaceutical combinations). The application designates all EPO member states plus several additional European countries, establishing a broad territorial scope for potential patent protection.

Pharmaceutical companies and research organisations developing benzodiazepinone-based therapeutics or oncology treatments should review this publication to assess potential freedom-to-operate implications. The designation of all major European jurisdictions means that any resulting patent could block competing products across the EU market. Parties conducting similar research in this chemical class should evaluate the scope of the disclosed claims and consider prior art searches to determine whether the application can be opposed at the grant stage.